Advertisement

The Latest

Johnson & Johnson and Synthes have entered into a definitive agreement, in which Johnson & Johnson will acquire Synthes for $21.3 billion, according to a company news release.

NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, has posted fourth quarter total revenue of $2.3 million, according to a company news release.

Advertisement